

Clinical trials of glitazone

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---------------------------|
| rosiglitazone vs | | | |
| AVM100264 [NCT00359112] n=294/302 follow-up: 52 wk | Rosiglitazone and metformin versus Metformin and sulfonylurea | Overweight patients with type 2 DM poorly controlled on Met | Parallel groups |
| BRL 49653C/185 n=563/142 follow-up: 32 wk | Rosiglitazone with or without metformin versus Usual care with or without metformin | patients with type 2 diabetes | Parallel groups |
| SB-712753/007 n=314/154 follow-up: 32 wk | Rosiglitazone with or without metformin versus Metformin | patients with type 2 diabetes without previous drug therapy | Parallel groups |
| SB-712753/009 n=162/160 follow-up: 24 wk | Rosiglitazone, metformin, and insulin versus Insulin | patients with type 2 diabetes with insulin | Parallel groups |
| rosiglitazone vs control | | | |
| Wang , 2005 n=NA follow-up: 6 months | rosiglitazone 4 mg/d versus control | patients with diabetes and CAD who had undergone percutaneous coronary intervention | Parallel groups open |
| rosiglitazone vs glyburide | | | |
| 49653/020 n=391/207 follow-up: 52 wk | Rosiglitazone versus Glyburide | patients with type 2 diabetes | Parallel groups |
| 49653/079 n=203/106 follow-up: 26 wk | Rosiglitazone with or without glyburide versus Glyburide | patients with type 2 diabetes poorly controlled on maximum dose of Gly | Parallel groups |
| 49653/080 n=104/99 follow-up: 156 wk | Rosiglitazone versus Glyburide | patients with type 2 diabetes | Parallel groups |
| 49653/097 n=122/120 follow-up: 156 wk | Rosiglitazone versus Glyburide | patients with type 2 diabetesDM | Parallel groups |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|---|--|----------------------------------|
| 49653/143 [NCT00333723] n=121/124 follow-up: 24 wk | Rosiglitazone and glyburide versus Glyburide | Type 2 DM poorly controlled on glyburide | Parallel groups |
| rosiglitazone vs glyburide (add on MET) | | | |
| 49653/137 [NCT00500955] n=204/185 follow-up: 32 wk | Rosiglitazone and metformin versus Glyburide and metformin | patients with type 2 diabetes | Parallel groups |
| pioglitazone vs metformin | | | |
| EC404 n=597/597 follow-up: 52 wk | Pioglitazone versus Metformin | patients with type 2 diabetes | Parallel groups |
| rosiglitazone vs metformin | | | |
| 49653/093 n=213/109 follow-up: 26 wk | Rosiglitazone with or without metformin versus Metformin | patients with type 2 diabetes poorly controlled on Met | Parallel groups |
| 49653/094 n=232/116 follow-up: 26 wk | Rosiglitazone and metformin versus Metformin | Type 2 DM poorly controlled on Met | Parallel groups |
| pioglitazone + sulfonyleurea vs metformin + sulfonyleurea | | | |
| EC409 n=319/320 follow-up: 104 wk | Pioglitazone + sulfonyleurea versus Metformin + sulfonyleurea | patients with type 2 diabetes | Parallel groups |
| rosiglitazone vs metformin/sulfonyleurea | | | |
| RECORD , 2013 [NCT00379769] n=NA follow-up: | - | - | |
| pioglitazone vs placebo | | | |
| PROACTIVE [NCT00174993] n=2605/2633 follow-up: 34.5 months | oral pioglitazone titrated from 15 mg to 45 mg versus placebo | patients with type 2 diabetes who had evidence of macrovascular disease. | |
| IRIS , 2016 [NCT00091949] n=NA | - | - | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|--|---|--|
| PNFP-001 n=329/79 follow-up: 26 wk | Pioglitazone versus Placebo | patients with type 2 diabetes | Parallel groups |
| PNFP-012 n=176/84 follow-up: 24 wk | Pioglitazone versus Placebo | patients with type 2 diabetes | Parallel groups |
| PNFP-026 n=101/96 follow-up: 16 wk | Pioglitazone versus Placebo | patients with type 2 diabetes | Parallel groups |
| PROactive , 2005 [NCT00174993] n=2605/2633 follow-up: 34.5 mo | pioglitazone titrated from 15 mg to 45 mg versus placebo | Inadequately controlled patients with type 2 diabetes who had evidence of macrovascular disease | Parallel groups double blind 19 European countries |
| rosiglitazone vs placebo | | | |
| 49653/011 n=357/176 follow-up: 24 wk | Rosiglitazone versus Placebo | patients with type 2 diabetes | Parallel groups |
| DREAM rosiglitazone , 2006 [NCT00095654] n=2365/2634 follow-up: 3 years (median) | rosiglitazone 8 mg daily versus placebo | patients with impaired fasting glucose or impaired glucose tolerance, or both | Parallel groups double blind 21 countries |
| 49653/128 n=39/38 follow-up: 28 wk | Rosiglitazone versus Placebo | patients with type 2 diabetes on concurrent Su | Parallel groups |
| 49653/134 n=561/276 follow-up: 28 wk | Rosiglitazone versus Placebo | patients with type 2 diabetes on Gly and Met | Parallel groups |
| 49653/136 n=148/143 follow-up: 26 wk | Rosiglitazone versus Placebo | patients with type 2 diabetes and chronic renal failure on Su, insulin, or both | Parallel groups |
| 49653/330 n=1/382 follow-up: 52 wk | Rosiglitazone versus Placebo | Chronic psoriasis | Parallel groups |
| 49653/331 n=706/325 follow-up: 52 wk | Rosiglitazone versus Placebo | Chronic psoriasis | Parallel groups |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|---|--|--|
| AVA100193 n=394/124 follow-up: 24 wk | Rosiglitazone versus Placebo | Mild-to-moderate Alzheimers disease | Parallel groups |
| BRL 49653/334 [NCT00306644] n=278/279 follow-up: 52 wk | Rosiglitazone versus Placebo | patients with type 2 diabetes or insulin resistance syndrome | Parallel groups |
| rosiglitazone and metformin vs placebo | | | |
| CANOE , 2010 [NCT00116932] n=103/104 follow-up: 3.9y (median) | rosiglitazone (2 mg) and metformin (500 mg) twice-daily versus placebo | patients with impaired glucose tolerance | Parallel groups double-blind |
| troglitazone vs placebo | | | |
| TRIPOD (Buchanan) , 2002 n=133/133 follow-up: 30 months (median) | troglitazone 400 mg once daily versus placebo | Hispanic women with previous gestational diabetes | Parallel groups double blind USA |
| US DDP troglitazone (Knowler) , 2005 n=585/582 follow-up: 0.9 year | troglitazone versus double placebo | nondiabetic patients with elevated glucose and high risk for diabetes | Parallel groups double blind USA |
| rosiglitazone vs placebo (add on glicazide) | | | |
| 49653/145 n=231/242 follow-up: 26 wk | Rosiglitazone and gliclazide versus Gliclazide | patients with type 2 diabetes | Parallel groups |
| rosiglitazone vs placebo (add on glimepiride) | | | |
| 49653/234 n=116/61 follow-up: 26 wk | Rosiglitazone and glimepiride versus Glimepiride | patients with type 2 diabetes | Parallel groups |
| rosiglitazone vs placebo (add on glipizide) | | | |
| 49653/135 n=116/111 follow-up: 104 wk | Rosiglitazone and glipizide versus Glipizide | Elderly patients with type 2 DM | Parallel groups |
| rosiglitazone vs placebo (add on glyburide) | | | |
| 100684 [NCT01045590] n=43/47 follow-up: 52 wk | Rosiglitazone and glyburide versus Glyburide | Korean patients with type 2 DM | Parallel groups |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|----------------------------------|
| 49653/127 n=56/58 follow-up: 26 wk | Rosiglitazone and glyburide versus Glyburide | patients with type 2 diabetespoorly controlled on Gly | Parallel groups |
| 49653/162 n=168/172 follow-up: 26 wk | Rosiglitazone and glyburide versus Glyburide | patients with type 2 diabetes | Parallel groups |
| pioglitazone + insulin vs placebo (add on insulin) | | | |
| OPI-502 n=110/112 follow-up: 20 wk | Pioglitazone + insulin versus Placebo + insulin | Insulin-dependent DM-2 | Parallel groups |
| PNFP-014 n=379/187 follow-up: 16 wk | Pioglitazone insulin versus Placebo + insulin | patients with type 2 diabetes | Parallel groups |
| rosiglitazone vs placebo (add on insulin) | | | |
| 49653/085 n=138/139 follow-up: 26 wk | Rosiglitazone and insulin versus Insulin | patients with type 2 diabetes | Parallel groups |
| 49653/095 n=196/96 follow-up: 26 wk | Rosiglitazone and insulin versus Insulin | patients with type 2 diabetes poorly controlled on insulin | Parallel groups |
| BRL 49653/347 [NCT00054782] n=418/212 follow-up: 24 wk | Rosiglitazone and insulin versus Insulin | patients with type 2 diabetes poorly controlled on insulin | Parallel groups |
| pioglitazone + metformin vs placebo (add on MET) | | | |
| PNFP-027 n=168/160 follow-up: 16 wk | Pioglitazone + metforminrea versus Placebo +metformin | patients with type 2 diabetes | Parallel groups |
| rosiglitazone vs placebo (add on MET) | | | |
| 49653/284 [NCT00501020] n=382/384 follow-up: 24 wk | Rosiglitazone and metformin versus Metformin | patients with type 2 diabetes | Parallel groups |
| 712753/008 [NCT00241605] n=284/135 follow-up: 48 wk | Rosiglitazone and metformin versus Metformin | Type 2 DM poorly controlled on Met | Parallel groups |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|--|--|----------------------------------|
| SB-712753/002 n=288/280 follow-up: 24 wk | Rosiglitazone and metformin versus Metformin | patients with type 2 diabetes poorly controlled | Parallel groups |
| SB-712753/003 n=254/272 follow-up: 32 wk | Rosiglitazone and metformin versus Metformin | Mild type 2 DM | Parallel groups |
| rosiglitazone vs placebo (add on SU) | | | |
| 49653/015 n=395/198 follow-up: 24 wk | Rosiglitazone and sulfonylurea versus Sulfonylurea | patients with type 2 diabetes | Parallel groups |
| 49653/125 [NCT00422955] n=175/173 follow-up: 26 wk | Rosiglitazone and sulfonylurea versus Sulfonylurea | patients with type 2 diabetes | Parallel groups |
| 49653/132 n=442/112 follow-up: 24 wk | Rosiglitazone and sulfonylurea versus Sulfonylurea | Patients in China with type 2 DM | Parallel groups |
| 49653/147 n=89/88 follow-up: 26 wk | Rosiglitazone and sulfonylurea versus Sulfonylurea | Indo-Asian patients with type 2 diabetes | Parallel groups |
| pioglitazone vs rosiglitazone | | | |
| GLAI [NCT00331487] n=369/366 follow-up: 24 wk | Pioglitazone versus Rosiglitazone | patients with type 2 diabetes and dyslipidemia | Parallel groups |
| pioglitazone vs sulfonylurea | | | |
| EC405 n=624/626 follow-up: 52 wk | Pioglitazone versus Sulfonylurea | patients with type 2 diabetes | Parallel groups |
| OPI-501 n=251/251 follow-up: 56 wk | Pioglitazone versus Sulfonylurea | Recently diagnosed DM-2 | Parallel groups |
| OPI-504 [NCT00521820] n=262/256 follow-up: 24 wk | Pioglitazone versus Sulfonylurea | patients with type 2 diabetes and mild to moderate congestive heart failure | Parallel groups |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---------------------------------------|
| OPI-506 [NCT00494312] n=1051/1046 follow-up: 156 wk | Pioglitazone versus Sulfonylurea | Inadequately controlled DM-2 | Parallel groups |
| OPI-520 [NCT00521742] n=151/149 follow-up: 52 wk | Pioglitazone versus Sulfonylurea | Inadequately controlled DM-2 with mild cardiac disease(New York Heart Association Class I) | Parallel groups |
| pioglitazone + sulfonylurea vs sulfonylurea | | | |
| PNFP-010 n=373/187 follow-up: 16 wk | Pioglitazone + sulfonylurea versus Sulfonylurea | patients with type 2 diabetes | Parallel groups |
| pioglitazone + metformin vs sulfonylurea + metformin | | | |
| EC410 n=317/313 follow-up: 104 wk | Pioglitazone + metformin versus Sulfonylurea + metformin | patients with type 2 diabetes | Parallel groups |
| rosiglitazone vs usual care | | | |
| 49653/211 n=110/114 follow-up: 52 wk | Rosiglitazone and usual care versus Usual care | Type 2 DM with CHF | Parallel groups |
| pioglitazone vs vildagliptin | | | |
| Bolli , 2008 n=295/295 follow-up: 52 weeks | vildagliptin (50 mg b.i.d.) versus pioglitazone (30 mg daily) | - | |
| rosiglitazone pioglitazone vs placebo | | | |
| TIDE ongoing [NCT00879970] n=16000 follow-up: | pioglitazone or rosiglitazone versus placebo | patients with type 2 diabetes who have a history of or are at risk for cardiovascular disease | Factorial plan double-blind USA |
| pioglitazone vs standard glucose-lowering drugs | | | |
| PPAR ongoing [NCT00212004] n=NA follow-up: | pioglitazone versus sulfonylurea agents | diabetes patients with a history of prior myocardial infarction | Parallel groups Japan |
| glitazone vs conventional treatment | | | |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|--|--|--|---|
| PROactive , 2005 [NCT00174993] n=2605/2633 follow-up: 34.5 months | pioglitazone titrated 15-45 mg daily versus standard treatment | patients with type 2 diabetes who had evidence of macrovascular disease | Parallel groups double blind 19 countries |

More details and results :

- insulin sensitizers - glitazones for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q321>
- prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q341>
- insulin sensitizers - glitazones for diabetes type 2 in patients with cardiovascular disease at <http://www.trialresultscenter.org/go-Q376>
- insulin sensitizer for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q377>
- insulin sensitizer for diabetes type 2 in patients with cardiovascular disease at <http://www.trialresultscenter.org/go-Q378>
- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- prevention for diabetes type 2 in people with impaired glucose tolerance at <http://www.trialresultscenter.org/go-Q416>
- intensive therapy for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q459>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled with insulin at <http://www.trialresultscenter.org/go-Q513>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>
- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>
- glucose lowering for cardiovascular prevention for diabetes type 2 in meta-regression at <http://www.trialresultscenter.org/go-Q692>

References

AVM100264 , :

BRL 49653C/185 , :

SB-712753/007 , :

SB-712753/009 , :

Wang, 2005:

Wang G, Wei J, Guan Y, Jin N, Mao J, Wang X, Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. *Metabolism* 2005;54:590-7. [[15877288](#)] [10.1016/j.metabol.2004.11.017](#)

49653/020 , :

49653/079 , :

49653/080 , :

49653/097 , :

49653/143 , :

49653/137 , :

EC404 , :

49653/093 , :

49653/094 , :

EC409 , :

RECORD, 2013:

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet* 2009 Jun 20;373:2125-35 [[19501900](#)]

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. *N Engl J Med* 2007 Jul 5;357:28-38 [[17551159](#)]

Mahaffey KW, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J, Newby LK, Komajda M, McMurray J, Bigelow R, Home PD, Lopes RD Results of a reevaluation of cardiovascular outcomes in the RECORD trial. *Am Heart J* 2013 Aug;166:240-249.e1 [[23895806](#)]

PROACTIVE , :

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korny L, Laakso M, Mokn M, Norkus A, Pirags V, Po Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005;366:1279-89 [[16214598](#)]

IRIS, 2016:

Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Sp Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. *N Engl J Med* 2016 Apr 7;374:1321-31 [[26886418](#)] [10.1056/NEJMoa1506930](#)

PNFP-001 , :

PNFP-012 , :

PNFP-026, :

PROactive, 2005:

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Morkan M, Norkus A, Pirags V, Po Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 Oct 8;366:1279-89 [[16214598](#)]

49653/011 , :

DREAM rosiglitazone, 2006:

Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 Sep 23;368:1096-105 [[16997664](#)]

49653/128 , :

49653/134 , :

49653/136 , :

49653/330 , :

49653/331 , :

AVA100193 , :

BRL 49653/334 , :

CANOE, 2010:

Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010 Jul 10;376:103-11 [[20605202](#)] [10.1016/S0140-6736\(10\)60746-5](#)

TRIPOD (Buchanan), 2002:

Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-803 [[12196473](#)]

US DDP troglitazone (Knowler), 2005:

Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-6 [[15793255](#)]

49653/145 , :

49653/234 , :

49653/135 , :

100684 , :

49653/127 , :

49653/162 , :

OPI-502, :

PNFP-014, :

49653/085 , :

49653/095 , :
BRL 49653/347 , :
PNFP-027, :
49653/284 , :
712753/008 , :
SB-712753/002 , :
SB-712753/003 , :
49653/015 , :
49653/125 , :
49653/132 , :
49653/147 , :
GLAI, :
EC405, :
OPI-501, :
OPI-504, :
OPI-506, 0:
OPI-520, :
PNFP-010, :
EC410, :
49653/211 , :
Bolli, 2008:

Bolli G, Dotta F, Rochotte E, Cohen SE Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. *Diabetes Obes Metab* 2008;10:82-90 [[18034842](#)] [10.1111/j.1463-1326.2007.00820.x](#)

Bolli G, Dotta F, Colin L, Minic B, Goodman M Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Obes Metab* 2009;11:589-95 [[19515179](#)] [10.1111/j.1463-1326.2008.01023.x](#)

TIDE, :

ongoing trial NCT00879970

PPAR, :

ongoing trial NCT00212004

PROactive, 2005:

Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. *Diabetes Care* 2004;27:1647-53 [[15220241](#)]

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korny L, Laakso M, Mokn M, Norkus A, Pirags V, Po Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005;366:1279-89 [[16214598](#)] [10.1016/S0140-6736\(05\)67528-9](#)

Wilcox R, Kupfer S, Erdmann E Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008;155:712-7 [18371481] 10.1016/j.ahj.2007.11.029

2 percutaneous coronary intervention

| Trial | Treatments | Patients | Trials design and methods |
|---|------------------------------------|---|---------------------------------|
| rosiglitazone vs placebo | | | |
| PROVIDENCE <i>ongoing</i> [NCT00116792] n=NA follow-up: | Rosiglitazone versus placebo | type 2 diabetic patients with de Novo Coronary Lesions | Parallel groups double blind |

More details and results :

- restenosis prevention for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q318>

References

PROVIDENCE, :
ongoing trial NCT00116792

3 impaired fasting glucose

| Trial | Treatments | Patients | Trials design and methods |
|--|---|--|---|
| rosiglitazone vs placebo | | | |
| DREAM rosiglitazone , 2006 [NCT00095654] n=2365/2634 follow-up: 3 years (median) | rosiglitazone 8 mg daily versus placebo | patients with impaired fasting glucose or impaired glucose tolerance, or both | Parallel groups double blind 21 countries |
| rosiglitazone and metformin vs placebo | | | |
| CANOE , 2010 [NCT00116932] n=103/104 follow-up: 3.9y (median) | rosiglitazone (2 mg) and metformin (500 mg) twice-daily versus placebo | patients with impaired glucose tolerance | Parallel groups double-blind |

More details and results :

- prevention for impaired fasting glucose in all type of patients at <http://www.trialresultscenter.org/go-Q342>

References

DREAM rosiglitazone, 2006:

Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 Sep 23;368:1096-105 [16997664]

CANOE, 2010:

Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y, Hanley AJ Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010 Jul 10;376:103-11 [20605202] 10.1016/S0140-6736(10)60746-5

Entry terms: pioglitazone, Actos, rosiglitazone, Avandia, metformin, Metformin, Dimethylguanylguanidine, Dimethylbiguanidine, Glucophage, , troglitazone, linagliptin, Linagliptin, Tradjenta, BI 1356, BI1356, BI-1356,